Archives

Perfusfind S.L.

Abstract Purpose: Venoarterial extracorporeal membrane oxygenation (V-A ECMO) can be used to support severely ill patients with cardiogenic shock. While age is commonly used in patient selection, little is known..

Perfusfind S.L.

Abstract Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a powerful hemodynamic support strategy for patients with cardiogenic shock and out-of-hospital cardiac arrest (OHCA).  Given that significant proportions of patients presenting with..

Perfusfind S.L.

Abstract The use of extracorporeal membrane oxygenation (ECMO) to support patients with cardiac arrest, cardiogenic shock, and acute respiratory distress syndrome is rising worldwide.1 While ECMO may save the lives of..

Perfusfind S.L.

Abstract Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) is increasingly used to treat refractory cardiogenic shock, despite randomized clinical trials reporting no difference in outcomes., Although traditional ECMO pumps maintain a constant flow..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) is a critical clinical syndrome  characterized by inadequate tissue perfusion and oxygen  delivery resulting from severe heart dysfunction, leading  to multi-organ failure. Diagnostic criteria include hypoperfusion..

Perfusfind S.L.

Abstract Background Monitoring fluid therapy is challenging in patients assisted with Veno-arterial ECMO. The aim of our study was to evaluate the usefulness of capillary refill time to assess the..

Perfusfind S.L.

Abstract Background The present article describes three cases of patients in cardiogenic shock (CS) with previous cardiac surgery that made them initially inoperable. Perioperative support with veno-arterial extracorporeal membrane oxygenation..

Perfusfind S.L.

Abstract Background The efficacy of extracorporeal membrane oxygenation (ECMO) as a bridge to left ventricular assist device (LVAD) remains unclear, and recipients of the more contemporary HeartMate 3 (HM3) LVAD..

Perfusfind S.L.

Abstract Purpose: The outcomes of immunocompromised patients with cardiogenic shock treated with venoarterial extra‑corporeal membrane oxygenation (VA‑ECMO) are seldom documented, making ECMO candidacy decisions challeng‑ing. This study aims (1) to..

Perfusfind S.L.

Abstract Background This study examines the role of extracorporeal life support flow in the development of acute kidney injury in cardiogenic shock. Methods We performed a retrospective analysis of 465..

Perfusfind S.L.

Abstract Background Out-of-hospital cardiac arrest (OHCA) remains a frequent medical emergency with low survival rates even after a return of spontaneous circulation (ROSC). Growing evidence supports formation of dedicated teams..

Perfusfind S.L.

Introduction Extracorporeal membrane oxygenation (ECMO) is increasingly used for circulatory or pulmonary support not only in-hospital but also out-of-hospital. Small dimensions and a lightweight design are important, especially for out-of-hospital..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) is a complex and life‐threatening condition characterized by a sudden and profound reduction in cardiac output, leading to inadequate tissue perfusion and oxygen delivery and organ..

Perfusfind S.L.

Abstract National trends show rapid increases in the use of mechanical circulatory support devices (MCSD) over the last 20 years. While current literature has not proven a mortality benefit in..

Perfusfind S.L.

Abstract Purpose: Venoarterial extracorporeal membrane oxygenation (V-A ECMO) can be used to support severely ill patients with cardiogenic shock. While age is commonly used in patient selection, little is known..

Perfusfind S.L.

Abstract Left ventricular (LV) unloading has been shown to improve survival for patients requiring veno-arterial extracorporeal membrane oxygenation (VA ECMO) support for cardiogenic shock. A mortality benefit has been shown..

Perfusfind S.L.

Abstract Background There is considerable debate about the hemodynamic effects of veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Aims To evaluate the changes in left ventricular (LV) function, volumes, and work in..

Perfusfind S.L.

Abstract Topic The growing use of acute mechanical circulatory support devices to provide hemodynamic support that has accompanied the increasing prevalence of heart failure and cardiogenic shock, despite significant improvement..

Perfusfind S.L.

Abstract Background Venoarterial extracorporeal membrane oxygenation (ECMO) provides full hemodynamic support for patients with cardiogenic shock, but optimal timing of ECMO initiation remains uncertain. We sought to determine whether earlier..

Perfusfind S.L.

Abstract Peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used in patients suffering from refractory cardiogenic shock (CS). Although considered life-saving, peripheral VA-ECMO may also be responsible for intracardiac..

Perfusfind S.L.

Abstract Long-term neuropsychiatric symptoms as well as neurologic and functional impairment are common in patients who receive extracorporeal membrane oxygenation (ECMO) support, results of a new meta-analysis showed. More than..

Perfusfind S.L.

Abstract Purpose: Cardiogenic shock is associated with high mortality. In refractory shock, it is unclear if mechanical circulatory support (MCS) devices improve survival. We conducted a network meta-analysis to determine..

Perfusfind S.L.

Abstract Background The present article describes three cases of patients in cardiogenic shock (CS) with previous cardiac surgery that made them initially inoperable. Perioperative support with veno-arterial extracorporeal membrane oxygenation..

Perfusfind S.L.

Abstract Introduction Critically ill patients supported with venoarterial  (VA ECMO) are at risk of developing severe arterial , which has been associated with increased mortality. Lower saturation targets in this population may..

Perfusfind S.L.

Abstract Cardiogenic shock is a complex and diverse pathological condition characterized by reduced myocardial contractility. The goal of treatment of cardiogenic shock is to improve abnormal hemodynamics and maintain adequate..

Perfusfind S.L.

Abstract Introduction In children with myocarditis or dilated cardiomyopathy (DCM) on extracorporeal membrane oxygenation (ECMO) for cardiogenic shock, it is often necessary to decompress the left heart to minimize distension..

Perfusfind S.L.

Abstract Background Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO) is a rescue treatment in refractory cardiogenic shock (CS) or refractory cardiac arrest (CA). Exposure to hyperoxemia is common during VA-ECMO, and its..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use for circulatory support in cardiogenic shock results in increased left ventricular (LV) afterload. The use of concomitant Impella or intra-aortic balloon pump (IABP)..

Perfusfind S.L.

Abstract Despite extracorporeal membrane oxygenation (ECMO) utilization in nearly 20% of cases, there are limited data in children with acute fulminant myocarditis (AFM) requiring ECMO. Herein we identify risk factors..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (VA-ECMO) initiation for patients with cardiogenic shock or cardiac arrest is an attractive strategy since it provides a quick restoration of organ perfusion. One major..